Sections & Products

Main > > >OPHTHALMOLOGY. *

Artificial Iris. (D)
USA Approval Date: 2018. 05.30.
(*) Company : HumanOptics AG.
TradeMark: CustomFlex
UpDate: 2018. 06.26.

Blepharitis. Anterior Blepharitis.
Treat. Device.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.22.

Blepharitis. Eye Examination Device.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.22.

Blepharitis. Treat.: HOCl Solution. (U)
UAE Approval Date: 2018. 01.09.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 07.03.

Cataract Surgery. Anesthesia. Midazolam+ +Ketamine.HCl+Ondansetron SubLingual Form. (U)
Availability: Yes.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 03.28.

Cataract Surgery. IntraOcular Lens (IOL)
>LAL> .. (U)
PostSurgery Refractive Correction.
EU Approval Date : ?
USA Approval Date: 2017. 11.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Cataract Surgery. or IntraOcular Lens Replacement (ILR)
Phenylephrine+Ketorolac Inj. (1%/0.3%)
(U)
- Indications:
maintaining pupil size by preventing
intraoperative miosis and reducing
postoperative ocular pain.
- Usage:
added to ophthalmic irrigation
solution
- Adults:
EU Approval Date : 2015. 08.03.
USA Approval Date: 2014. 06.02.
USA Launch Date: 2015. 04.02.
- Pediatrics:
USA Approval Date: 2017. 12.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2018. 07.02.

Clinical Trials Access from Home.
FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible.
Using the Apple ResearchKit platform, Company is making FocalView vision tests freely available to the scientific community.
Launch Date: 2018. 04.25.
(*) Company: Novartis.
UpDate: 2018. 04.26.

Daily Disposable Silicone Hydrogel (SiHy) Contact Lenses.
AU; NZ Launch Date 2019. 03.
USA Launch Date: 2019. 08.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.05.

Diabetic Macular Edema (DME) Treat.:
Dexamethasone Intravitreal Implant. (I)
CN Approval Date : 2017. 10.30.
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Diabetic Macular Edema (DME) Treat.:
Fluocinolone Acetonide IntraVitreal Implant. (U)
EU Approval Date : 2015. 04.14.
FI Launch Date : 2021. 02.18.
IE Launch Date : 2017. 09.12.
NL Launch Date : 2020. 12.09.
USA Approval Date: 2014. 09.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.15.

Diabetic Macular Edema (DME). Treat.:
RanibizuMAb Injection. (U)
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2018. 07.02.

Diabetic Retinopathy. DIAG.: Artificial
Intelligence (AI). (U>E)
CA Approval Date : 2018. 03.08.
EU Approval Date : 2015. 04.14.
USA Approval Date: 2020. 08.05.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 08.06.

Diabetic Retinopathy. DIAG.: Artificial
Intelligence (AI).
USA Approval Date: 2018. 04.12.
(*) Company : IDx Inc.
Web-Site :
www.eyediagnosis.net/diabetes
UpDate: 2018. 04.13.

Diabetic Retinopathy. DIAG.: Artificial
Intelligence (AI)+TeleHealth. (U>2).
(*) Company; Patents & Web-Sites Avai-
lable on Request.
UpDate: 2018. 10.14.

Diabetic Retinopathy (DR). TREAT.:
RanibizuMAb Inj. (U)
USA (PFS) Approval: 2018. 03.21.
USA Approval : 2017. 04.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Disease Research.
KnowledgeBase, a DataBase with more than 500,000 clinical phenotype records.
Launch Date: 2018. 04.27.
(*) Company : MedGenome Inc.
www.medgenome.com
TradeMark: Ophthatome
UpDate: 2018. 04.28.

Dry Age-related Macular Degeneration (AMD). TREAT.: PhotoBioModulation (PBM) Therapy. (U)
EU Approval Date: 2018. 06.22.
(*) Company; Patent APPs.; Product Na-
me & Web-Site Available on Request.
UpDate: 2018. 06.23.

Dry Eye Syndrome. Eyelid Cleanser.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.05.

Dry Eye Syndrome. Relief. Nutritional
Formula. (U)
Launch Date: 2018. 02.27.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.03.

Dry Eye Syndrome. Treat.: Cyclosporin A.
(I)
USA Approval Date: 2018. 08.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.17.

Dry Eye Syndrome. Treat.: Cyclosporin E.
(I)
CA Approval Date : ?
USA Approval Date: 2002. 12.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Dry Eye Syndrome. Treat.: Cyclosporin S.
(D)
AT Launch Year : 2015.
AU Approval Date: 2017. 10.30.
DE Launch Year : 2015.
EU Approval Date: 2013. 07.23.
NZ Launch Date : 2017. 10.30.
(*) Companies; Patent; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 07.02.

Dry Eye Syndrome. Treat.: Lifitegrast
Solution 5%. (U)
CA Approval Date : 2018. 01.03.
USA Approval Date: 2016. 07.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.03.

EyeWear. High Energy Visible (HEV) 450 nm Peak Clear Absorbing Coating. (U)
(*) Company; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2018. 07.02.

Genetic Disease. Treat.: Voretigene Neparvovec rzyl. (U)
(Inherited Retinal Disease due to Mutations in Both Copies of the RPE65 gene)
USA Approval Date: 2017. 12.19.
(*) Companies; Patent; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 07.03.

Glaucoma. Open-Angle Glaucoma. Intra-
Ocular Pressure. Lowering. BimatoProst.
Implant. IntraCameral.
USA Approval Date: 2020. 03.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.06.

Glaucoma. Open-Angle Glaucoma. Intra-
Ocular Pressure. Lowering. LatanoPros-
tene 0.024% Solution. (U)
Prostaglandin Analog.
USA Approval Date: 2017. 11.02.
USA Launch Date : 2017. 12.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.01.

Glaucoma. Open-Angle Glaucoma. Intra-
Ocular Pressure. Lowering. Netarsudil Ophthalmic Solution 0.02%. (U)
USA Approval Date: 2017. 12.18.
USA Launch Date: 2018. 04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.14.

Glaucoma. Open-Angle Glaucoma. Intra-
Ocular Pressure. Lowering. Netasurdil &
Latanaprost Ophthalmic Solution 0.02%/
0.005%. (U)
EU Approval Date: 2021. 01.11.
USA Approval Date: 2019. 03.12.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2021. 03.10.

Glaucoma. Treat.: Micro-Invasive Glau-
coma Surgery (MIGS). Stent System.
Description:
tiny implant to restore eye s natural ability to drain fluid out of the eye to reduce glaucoma pressure. Designed for patients with cataracts & glaucoma & implanted at time of cataract surgery.
1st Generation>
>USA Approval Date: 2012. 06.25.
2nd Generation>
>Also Comm. Available in: AU; BR; CA;
>EU; HK; SG & ZA
>USA Approval Date: 2018. 06.25.
>Size>0.23 mm x 0.36 mm 1/3 1st Gen.
(*) Company; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2018. 08.23.

Human 11-Plex Ophthalmology Kit.
Launch Date: 2017. 12.05.
(*) Company : AYOXXA Biosystems GmbH.
TradeMark: Lunaris.
UpDate: 2018. 07.02.

Imaging. UltraSound. Device. (U)
EU Approval Date : 2016. 04.26.
USA Approval Date: 2016. 02.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Myopic Choroidal NeoVascularization.
TREAT.: RanibizuMab Inj. (U)
USA Approval Date: 2017. 01.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Neurotrophic Keratitis (NK). TREAT.:
Cenegermin Eye Drops.
Recombinant Human Nerve Growth Factor.
EU Approval Date : 2017. 07.06.
USA Approval Date: 2018. 08.22.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 08.27.

Ocular>TeleHealth (U>2).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.14.

Ocular>TeleHealth (U>D).
(*) Company; Patent; & Web-Site
Available on Request.
UpDate: 2018. 10.14.

PostSurgical Inflammation. Treat.: Lote- prednol Etabonate Ophthalmic Suspension, 0.5%. Generic.
USA Approval Date: 2019. 04.18.
Company: Akorn Inc.
UpDate: 2019. 04.20.

PostSurgical Pain. Treat.: Dexamethasone
Intracanalicular Insert.
USA Approval Date: 2018. 12.03.
(*) Company : Ocular Therapeutix.
TradeMark: DEXTENZA
UpDate: 2018. 12.04.

Presbyopia. TREAT.: Laser .. (U)
USA 510(k) Clearance Date: 2018. 04.11.
(*) Company; Patent & PR Web-Site
Available on Request.
UpDate: 2018. 04.12.

Uveitis. Treat.: Dexamethasone Intra- Vitreal Implant. (I)
CN Approval Date : 2017. 10.30.
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.02.

Visual Processing Assessing Method &
System.
Commercial Release: 2017. 05.25.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.19.

Wet Age-related Macular Degeneration (AMD). Diagnostic & Monitoring. (U)
USA Approval Date: 12.28.2009.
USA Launch Date : ?
Home Use Device.
Test Duration: 3 Min. Per Eye
Test Frequency: Daily Basis
(*) Company; Patents; TradeMarks &
Web-Sites Available on Request
UpDate: 2018. 07.03.

Wet Age-related Macular Degeneration (AMD). Monitoring. Optical Coherence Tomography (OCT) "MOBILE SELF"-Scanner. (C)
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 07.05.

Wet Age-related Macular Degeneration (AMD). Treat.: Adjunctive RadioTherapy
(RT). Low Energy X-Ray Therapy. (D)
[as a one-time procedure to reduce or eliminate the need for frequent anti-vascular endothelial growth factor (anti-VEGF) injections directly into the eye, which are costly and burdensome for patients and clinicians alike]
Availability: CH; DE; GR & UK.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 07.05.

Wet Age-related Macular Degeneration (AMD). Treat.: Aflibercept Inj. (U>R)
(IntraVitreal Injection)
VEGF Inhibition/Trap.
AU Approval Date : ?
CA Approval Date : 2013. 12.11.
USA Approval Date: 2011. 12.05.
USA Approval Date: 2018. 08.17.
(Once Every 3 Months)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.18.

Wet Age-related Macular Degeneration (AMD). Treat.: Pegaptanib Na Inj. (U>B)
PEGylated Aptamer RNA OligoNucleotide
VEGF Inhibition
USA Approval Date: 12.2004.
(*) Company : Bausch & Lomb Inc.
Patent : Expired
TradeMark: Macugen
UpDate: 2018. 07.04.

Wet Age-related Macular Degeneration (AMD). Treat.: RanibizuMAb Inj. (U>G)
VEGF Inhibition
USA Approval Date: 2006. 06.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.04.

>OPHTHALMOLOGY. *'s products
This section has no products